According to a recent LinkedIn post from Glooko, the company is positioning its diabetes and glycemic management platforms as tools that can help health systems connect inpatient and outpatient data streams. The post ties this opportunity to the American Diabetes Association’s 2026 Standards of Care in Diabetes, which are described as encouraging greater integration of these data environments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that Glooko and EndoTool, from Monarch Medical Technologies, a Glooko company, together may support a more “actionable ecosystem” for diabetes care. For investors, this framing suggests a strategy focused on enterprise health systems and large‑scale care transformation, which could expand Glooko’s addressable market if providers accelerate adoption to meet evolving standards.
The emphasis on managing and supporting patients “today and in the future” implies an ongoing role for the platforms in both current workflows and longer‑term digital health infrastructure. This could reinforce recurring revenue potential from software and data services, though actual financial impact will depend on contract wins, integration success with hospital IT systems, and competitive responses in the diabetes management technology space.